Biotechnology

NewcelX

NewcelX Submits Patent Application for Novel Compound DOXA in China

NewcelX Advances Clinical Trials and Announces Strategic and Clinical Progress

Kadimastem Ltd released FY2025 Semi-Annual earnings on August 31, 2025, EST with actual revenue of USD 0 and EPS of USD -2.6379

Kadimastem Ltd released FY2025 Q1 earnings on August 31 (EST), actual revenue USD 0, actual EPS USD -1.2616

Kadimastem Ltd released FY2024 Semi-Annual earnings on August 31 (EST), actual revenue USD 0, actual EPS USD -0.2947

Kadimastem Ltd released FY2024 Q2 earnings on August 31, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.1456

Kadimastem Ltd released FY2024 Q1 earnings on August 31, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.149

Kadimastem Ltd released FY2025 Q2 earnings on August 31 (EST), actual revenue USD 0, actual EPS USD -1.3762

Kadimastem Ltd released FY2022 earnings on March 31 (EST) with actual revenue of USD 0 and EPS of USD -1.8973

Kadimastem Ltd released FY2023 Annual Earnings on March 31 (EST), Actual Revenue: USD 0, Actual EPS: USD -0.7769

Kadimastem Ltd released FY2024 Annual Earnings on March 31, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.7063

Kadimastem Ltd released FY2024 Q4 earnings on March 31, 2025 (EST), actual revenue USD 0, actual EPS USD -0.7174

Kadimastem Ltd released FY2023 Q4 earnings on March 31, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1633

Kadimastem Ltd released FY2023 Q3 earnings on March 31, 2025 (EST), actual revenue USD 0, actual EPS USD -0.1544

Kadimastem Ltd released FY2022 Q4 earnings on March 31, 2025 (EST), actual revenue USD 0, actual EPS USD -0.4061

Kadimastem Ltd released FY2024 Q3 earnings on March 31 (EST), actual revenue USD 0, actual EPS USD -0.7029

Kadimastem Ltd released FY2024 9 Months Earnings on March 31 (EST), actual revenue USD 0, actual EPS USD -0.9977

Processa Pharmaceuticals

Agape ATP

cbdMD

VYNE Therapeutics

Inspirato

Mega Fortune

Globavend

Andersen

DingDong

Udemy

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap